SynthesisThe Cochrane database of systematic reviews2022
Impact of low-dose computed tomography (LDCT) screening on lung cancer-related mortality.
Synthesis in The Cochrane database of systematic reviews, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06070922 (Role Of LDCT Chest In Assessment Of Apparently Healthy Smokers), which is not on this map. Cited by 123 papers, 10 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Role Of LDCT Chest In Assessment Of Apparently Healthy Smokers
Who cites it
123 citing papers in PubMed, 10 syntheses or guidelines pooled it, 141 citations in OpenAlex.
- ESR Essentials: lung cancer screening with low-dose CT-practice recommendations by the European Society of Thoracic Imaging.European radiology · 2026Guideline
- Screening for lung cancer: A systematic review of overdiagnosis and its implications.Molecular oncology · 2026Pooled it
- Health-related quality of life assessment in trials testing tyrosine kinase inhibitors or immune checkpoints inhibitors in early-stage NSCLC.The oncologist · 2025Pooled it
- An umbrella review of systematic evidence on the Low Dose Computed Tomography (LDCT) for lung cancer screening.Future oncology (London, England) · 2025Pooled it
- Time to Benefit for Lung Cancer Screening: A Systematic Review and Survival Meta-Analysis.American journal of preventive medicine · 2025Pooled it
- Current status, hotspots, and trends in cancer prevention, screening, diagnosis, treatment, and rehabilitation: A bibliometric analysis.Oncology research · 2025Pooled it
- Agreement Between Mega-Trials and Smaller Trials: A Systematic Review and Meta-Research Analysis.JAMA network open · 2024Pooled it
- Pooled it
- [China National Lung Cancer Screening Guideline with Low-dose Computed Tomography (2023 Version)].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2023Guideline
- Impact of low-dose computed tomography (LDCT) screening on lung cancer-related mortality.The Cochrane database of systematic reviews · 2022Pooled it
- Effect of Lung Cancer Screening, Smoking Cessation, and Cessation Smartphone App to Health-Related Quality of Life Among Heavy Smokers: Randomized Controlled Trial.Journal of medical Internet research · 2026Trial
- Physical activity and lung cancer screening (PALS): feasibility randomised controlled trial of exercise and physical activity in lung cancer screening.Respiratory research · 2025Trial
- Validation of the psychosocial consequences of screening in lung cancer questionnaire in the international lung screen trial Australian cohort.Health and quality of life outcomes · 2024Trial
- Anti-PDGFRα autoantibody - a novel diagnostic and prognostic marker - may mediate non-small cell lung cancer progression via the PI3K/AKT/NF-κB signaling pathway.British journal of cancer · 2026Article
- Pilot feasibility study to deliver low-dose CT lung cancer screening in Scotland: descriptive findings from the LungScot study.BMJ open · 2026Article
- Real-Time AI-Augmented Fluoroscopic Navigation for Intraoperative Pulmonary Nodule Localization: Prospective Observational Pilot Study.JMIR formative research · 2026Observational
- It depends on where you stand on screening: health professionals' awareness, perspectives, and approaches to overdiagnosis in cancer screening - a qualitative interview study.BMC health services research · 2026Article
- Over- and underscreening for lung cancer.Translational lung cancer research · 2026Review
- Lung cancer risk prediction models and asbestos exposure: a validation study on the Western Australia Asbestos Review Program.Occupational and environmental medicine · 2026Article
- Blood-based DNA methylation marker model for short-term and long-term lung cancer risk prediction.BMC medicine · 2026Article
63 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung cancer is the most common cause of cancer-related death in the world, however lung cancer screening has not been implemented in most countries at a population level. A previous Cochrane Review found limited evidence for the effectiveness of lung cancer screening with chest radiography (CXR) or sputum cytology in reducing lung cancer-related mortality, however there has been increasing evidence supporting screening with low-dose computed tomography (LDCT).
objectivesTo determine whether screening for lung cancer using LDCT of the chest reduces lung cancer-related mortality and to evaluate the possible harms of LDCT screening. SEARCH
methodsWe performed the search in collaboration with the Information Specialist of the Cochrane Lung Cancer Group and included the Cochrane Lung Cancer Group Trial Register, Cochrane Central Register of Controlled Trials (CENTRAL, the Cochrane Library, current issue), MEDLINE (accessed via PubMed) and Embase in our search. We also searched the clinical trial registries to identify unpublished and ongoing trials. We did not impose any restriction on language of publication. The search was performed up to 31 July 2021. SELECTION CRITERIA: Randomised controlled trials (RCTs) of lung cancer screening using LDCT and reporting mortality or harm outcomes. DATA COLLECTION AND ANALYSIS: Two review authors were involved in independently assessing trials for eligibility, extraction of trial data and characteristics, and assessing risk of bias of the included trials using the Cochrane RoB 1 tool. We assessed the certainty of evidence using GRADE. Primary outcomes were lung cancer-related mortality and harms of screening. We performed a meta-analysis, where appropriate, for all outcomes using a random-effects model. We only included trials in the analysis of mortality outcomes if they had at least 5 years of follow-up. We reported risk ratios (RRs) and hazard ratios (HRs), with 95% confidence intervals (CIs) and used the I
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.